1x 베팅 주소 Pharamaceutical Co., Ltd.

1x 베팅 주소 Co., Ltd. and its U.S.-based, indirect subsidiary Avanir Pharmaceuticals, Inc. announce that they have decided to continue the clinical development program of AVP-786 (a combination of deudextromethorphan hydrobromide and quinidine sulfate) for the treatment of agitation in patients with Alzheimer's dementia.

1x 베팅 주소 decision is based on insights derived from detailed analysis of data from 1x 베팅 주소 first and 1x 베팅 주소 second phase 3 AVP-786 clinical trials.*

1x 베팅 주소 ongoing third phase 3 clinical trial (17-AVP-786-305) will be continued, and additional phase 3 trial activity will be started in 1x 베팅 주소 2020.

* Preliminary results of 1x 베팅 주소 first and 1x 베팅 주소 second phase 3 clinical trials (15-AVP-786-301 and 15-AVP-786-302) were released March 25 and September 27, 2019, respectively.